Our top pick for
Advaxis, Inc is a biotechnology business based in the US. Advaxis shares (ADXS) are listed on the NASDAQ and all prices are listed in US Dollars. Advaxis employs 17 staff and has a trailing 12-month revenue of around USD$253,000.
|52-week range||USD$0.272 - USD$1.57|
|50-day moving average||USD$0.8214|
|200-day moving average||USD$0.509|
|Wall St. target price||USD$5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.094|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$253,000|
|Return on assets TTM||-35.31%|
|Return on equity TTM||-75.94%|
|Market capitalisation||USD$98.5 million|
TTM: trailing 12 months
There are currently 5.4 million Advaxis shares held short by investors – that's known as Advaxis's "short interest". This figure is 8.5% down from 5.9 million last month.
There are a few different ways that this level of interest in shorting Advaxis shares can be evaluated.
Advaxis's "short interest ratio" (SIR) is the quantity of Advaxis shares currently shorted divided by the average quantity of Advaxis shares traded daily (recently around 17.6 million). Advaxis's SIR currently stands at 0.31. In other words for every 100,000 Advaxis shares traded daily on the market, roughly 310 shares are currently held short.
However Advaxis's short interest can also be evaluated against the total number of Advaxis shares, or, against the total number of tradable Advaxis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Advaxis's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Advaxis shares in existence, roughly 50 shares are currently held short) or 0.0487% of the tradable shares (for every 100,000 tradable Advaxis shares, roughly 49 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Advaxis.
Find out more about how you can short Advaxis stock.
We're not expecting Advaxis to pay a dividend over the next 12 months.
Advaxis's shares were split on a 1:15 basis on 29 March 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Advaxis shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Advaxis shares which in turn could have impacted Advaxis's share price.
Over the last 12 months, Advaxis's shares have ranged in value from as little as $0.272 up to $1.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Advaxis's is 2.8597. This would suggest that Advaxis's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.